Shailaja Kasibhatla

USPTO Granted Patents = 23 (Patent Applications = 11)

EPO Patents = 4 (Patent Applications = 15)

Average Co-Inventor Count = 6.0

ph-index = 6

Forward Citations = 202(Granted Patents)

Company Filing History:

Myriad Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12396995 - Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use (2025-08-26),

2. 12180291 - Anti-CCR7 antibody drug conjugates (2024-12-31),

3. 12178822 - Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion (2024-12-31),

4. 11752162 - Compounds and compositions for treating solid tumors by intratumoral administration (2023-09-12),

5. 11666579 - Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2023-06-06),

6. 11634497 - Anti-CCR7 antibody drug conjugates (2023-04-25),

7. 11628172 - Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2023-04-18),

8. 11583536 - Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use (2023-02-21),

9. 10973826 - Antibody conjugates comprising toll-like receptor agonist (2021-04-13),

10. 10195208 - Combination therapy (2019-02-05),

11. 7968595 - Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof (2011-06-28),

12. 7618975 - 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2009-11-17),

13. 7592143 - Methods of treating diseases responsive to induction of apoptosis and screening assays (2009-09-22),

14. 7435750 - Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof (2008-10-14),

15. 7256219 - Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof (2007-08-14),

Shailaja Kasibhatla: Innovator in Antibody Drug Conjugates

Introduction

Shailaja Kasibhatla is a prominent inventor based in San Diego, CA, with a remarkable portfolio comprising 22 patents. Her innovative work focuses primarily on antibody drug conjugates, particularly in the field of cancer treatment. Kasibhatla’s inventions have the potential to significantly impact therapeutic approaches, underscoring her role as a trailblazer in biomedicine.

Latest Patents

Among her latest patents is the development of anti-CCR7 antibody drug conjugates. This application discloses anti-CCR7 antibodies, as well as antigen-binding fragments and antibody drug conjugates involving these antibodies. The invention outlines methods for treating or preventing cancer using these antibodies and their diagnostic applications. Another significant patent focuses on utilizing a compound, specifically 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, for treating hematological malignancies. This invention describes various methods for managing these cancers through innovative pharmaceutical approaches.

Career Highlights

Shailaja has contributed to various breakthroughs while working with leading companies in the industry. She has been part of the teams at Cytovia, Inc. and Novartis AG, where her expertise has driven significant advancements in pharmaceutical development. Her strong focus on antibody therapies has established her as a key figure in her field.

Collaborations

Throughout her career, Shailaja Kasibhatla has collaborated with esteemed colleagues, including Sui Xiong Cai and John A. Drewe. These partnerships have enhanced her research capabilities and innovation processes, leading to ground-breaking contributions to medical science.

Conclusion

Shailaja Kasibhatla embodies the spirit of innovation within the realm of biomedical research. With a growing patent portfolio and a commitment to developing novel therapeutic methods, she continues to pave the way for future advancements in the treatment of cancer and hematological diseases. Her work not only enhances our understanding but also holds the promise of improving patient outcomes through targeted therapies.

This text is generated by artificial intelligence and may not be accurate.